Skip to main content
OpenTrials
Completed

NCT Number: NCT00194688

Breath Ammonia Method for H. Pylori Detection: Phase II

The objective is to evaluate the utility of a breath ammonia sensing device. In this study we will assess the effect of H. pylori infection on breath ammonia levels by measuring whether there is a change in the pattern or quantity of breath ammonia seen in H. pylori positive patients compared to H. pylori negative patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

VA Puget Sound Health Care System

Seattle, Washington, 98108, United States

About this study

Healthy volunteers will undergo testing for H. pylori infection using a 14-C urea breath test, and the results will be compared to an experimental ammonia breath test. The breath sample will be collected by an investigational device that the patient will be exposed to consisting of a plastic mouth-piece which is attached to a T-tubing section having a side-arm port through which a fiberoptic ammonia sensor is inserted inside the tube. To meet the Phase II specific aim, the scope of the clinical trials is expanded addressing the following specific objectives:

  • Test refinements of the sensing system (hardware, software, & breath test device)
  • Determine whether a urea dose-response effect exists following urea ingestion,
  • Define the optimal cutoff values for expired breath ammonia to allow optimal discrimination of H. pylori infected vs. uninfected persons.
  • Determine the appropriate time interval for breath ammonia testing following urea ingestion.
  • Determine whether there is a change in breath ammonia level after H. pylori treatment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult volunteers not meeting exclusion criteria

Exclusion criteria

  • Known cirrhosis of the liver
  • Renal insufficiency (BUN greater than 40 mg/dl, Creatinine greater than 2.0 mg/dl).
  • Prior gastric resection
  • Severe chronic obstructive pulmonary disease (Forced expiratory volume in 1 second less than 1.5 L)
  • Patients unwilling or unable to discontinue proton pump inhibitors for 2 weeks prior to scheduled 14C or non-isotopic urea breath testing
  • Patients who have received antibiotics or bismuth within the preceding month.
  • Patients unwilling or unable to give informed consent
  • Pregnant women (14C urea breath test is not approved for use in pregnant women)
  • Age less than 21 years (14C urea breath test is not approved for use in children)

Treatment and study plan

H. pylori treatment

Drug

Primary outcomes

  1. Sensitivity and specificity of breath ammonia measurement for H. pylori infection

Secondary outcomes

  1. Determination of a dose response relationship for oral urea dose and breath ammonia level.

  2. Determination of whether breath ammonia measurement allows determination of successful H. pylori treatment.

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • National Institutes of Health (NIH)

Registry information

Important dates

Study start
2003
Study completion
2005
First posted
Sep 19, 2005
Registry last updated
Jan 11, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.